医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

NovellusDx and Primetech Sign an Exclusive Dealer Agreement in Japan

2018年09月04日 AM01:57
このエントリーをはてなブックマークに追加


 

TOKYO & JERUSALEM

NovellusDx, Ltd. (CEO: Haim Gil-Ad, headquarters: Jerusalem Bio-Park, Hadassah medical center, Ein-Kerem Campus, Israel) and Primetech Co., Ltd. (President: Ryosuke Ogihara, Head office: 1-3-25 Koishikawa, Bunkyo-ku, Tokyo, Japan) announce that Primetech will provide NovellusDx’ functional genomics assay “FACT – Functional Annotation for Cancer Treatment” as an exclusive dealer in Japan for the pre-clinical market with sales, marketing and research support / technical support in Japan.

“We are pleased to be represented by such a trusted and honorable name as Primetech,” said Haim Gil-Ad, NovellusDx CEO, “Japan is the first territory where we grant agent agreements. This echoes our strong belief that the Japanese oncology market is of the upmost importance.”

“Precision medicine is changing oncology worldwide,” said Ryosuke Ogihara, Primetech president, “optimizing targeted treatment strategy based on tumor molecular alteration is more efficacious than standard treatment based on tumor localization and being able to measure the activity of specific mutations and their response to drugs is revolutionary.”

“We are excited to offer NovellusDx’ functional oncology assay to our existing pharma and research center clients,” said Keiichi Teramoto, Director of Marketing, of Primetech. “The FACT system has a great ability to predict the clinical outcome of the patients in the complex real-life setting. Now we will be able to bring the system to our clients developing cancer drugs and mechanisms of action.”

“Today, genomic sequencing plays an ever-increasing role in cancer treatment, but the functional significance of most mutations found in a patient’s DNA is unknown and so is the effect drugs have on them,” said Michael Vidne CCO of NovellusDx. “Japan is a huge, advanced market with the top research centers and pharma companies operating here. It is an honor for us to be able and help them.”

About Primetech

Primetech is a manufacturer and distributor of high technology life-science research equipment throughout Japan for more than 30 years. Primetech has technically advanced staffs, and an intimate knowledge of the Japanese marketplace allow it to assist companies in penetrating the Japanese market. Primetech’s mission is to create true value for customers who research challenging issues in the advanced life science. Primetech provides better solutions to satisfy our customer needs and contribute to the progress and improvement of society with our prime technology and customer support.

Details: https://www.primetech.co.jp

About NovellusDx

NovellusDx’s mission is to provide functional information about mutations and their responses to drugs so that oncologists can treat patients with precision therapies and bio-pharmaceutical companies can develop drugs more effectively. The NovellusDx approach is to monitor the functional effects of mutations and observe the effects of drugs, drug combinations and drug candidates on the activity level caused by the mutations. NovellusDx’s headquarters and research and development operations are based in Jerusalem, Israel.

Details: https://www.novellusdx.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20180903005265/en/

CONTACT

NovellusDx
Michael Vidne
Michael@NovellusDx.com
or
Primetech
Keiichi
Teramoto
kteramot@primetech.co.jp

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • アルヴォテックと富士製薬が日本でバイオシミラーを開発・商業化するための独占提携契約を締結
  • Alvotech与富士制药缔结排他性伙伴关系,在日本从事生物类似物的开发和商业化
  • Dynex Technologies获得CFDA核准,向中国供应AGILITY自动ELISA处理系统
  • Alvotech and Fuji Pharma Enter into Exclusive Partnership for Development and Commercialization of Biosimilars in Japan
  • SANYEI CORPORATION Based in Japan Launches ION-Sei™ into the UK Market in Time for the Christmas Season. A Unique Electric Toothbrush That Uses Patented Technology to Suppress Bacteria That Cause Plaque and Gum Disease